Sasanlimab

Sasanlimab (PF-06801591) is a monoclonal antibody developed by Pfizer. Its targets are PD-1 and PD-L1 (the sponsor names PD-1). The sponsor states: A monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1/PD-L2. ClinicalTrials.gov describes the intervention as: A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04165317 (A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer), in bladder & urothelial cancer. The largest, NCT04165317, plans to enrol 1068 participants (actual) with primary completion expected 2024-12-02. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.